TROPION-Lung04

TROPION-Lung04, datopotamab deruxtecan, Dato-DXd, Imfinzi, NSCLC, International Association for the Study of Lung Cancer, IASLC 2023, Immunotherapy, antibody-drug conjugate

Datopotamab Deruxtecan + Imfinzi Transform First-Line NSCLC Treatment in TROPION-Lung04 Trial

Anika Sharma

The TROPION-Lung04 Phase Ib trial has unveiled highly promising results. The trial showcases the potential of datopotamab deruxtecan (Dato-DXd), in ...